贝达药业与博锐生物达成“曲帕双珠”全面合作 快速拓展乳腺肿瘤治疗市场

Group 1 - The core viewpoint of the news is the strategic partnership between Betta Pharmaceuticals and Borui Biotech for the commercialization of the drug "Qupashuangzhu" in the Greater China region, which includes exclusive rights for Betta to distribute trastuzumab (brand name: Anruize®) and all rights related to pertuzumab injection [1][4] - Breast cancer is highlighted as the most common malignant tumor among women, with trastuzumab being the first targeted monoclonal antibody drug for HER2-positive breast cancer, and pertuzumab being a recombinant humanized monoclonal antibody that enhances treatment efficacy [3] - The partnership is seen as a significant step in enhancing Betta's market position in breast cancer treatment and accelerating Borui's capabilities in developing large molecule drugs for oncology [4][5] Group 2 - Betta Pharmaceuticals' CEO expressed gratitude for the efforts of both teams, emphasizing that this collaboration marks a milestone in China's biopharmaceutical innovation and industry synergy [4] - The collaboration is expected to provide better treatment options and accessibility for breast cancer patients, aligning with Betta's mission to improve patient outcomes through innovation [4][6] - Borui Biotech's CEO noted that the successful collaboration is built on trust established during the Betanatin® project, and both companies aim to achieve synergistic effects through their combined strengths [5][6]